Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors

Launched by DAIICHI SANKYO CO., LTD. · Dec 3, 2013

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Advanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available.
• • Eastern Cooperative Oncology Group performance status(PS) of 0 or 1
• Exclusion Criteria:
• * Have any of the following concomitant disease or had the history of having following disease within 6 months before enrollment:
• • Cardiac failure (NYHA ≥ ClassIII), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary-artery/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deep-vein thrombosis or clinically severe thromboembolic event, or clinically severe pulmonary disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug induced pneumonia)
• • Severe or uncontrolled concomitant disease.
• • Clinically active brain metastases defined as symptomatic or requiring treatment.